Slow-Channel Congenital Myasthenic Syndrome Due to the Novel Variant c.1396G_A in CHRNA1 That Responds Favorably to 3,4-Diaminopyridine: A Case Report.
Finsterer J.
Cureus. 2024 Nov 13;16(11):e73601. doi: 10.7759/cureus.73601. eCollection 2024 Nov.
PMID:39677241
Fluoxetine is neuroprotective in slow-channel congenital myasthenic syndrome.
Zhu H, Grajales-Reyes GE, Alicea-Vázquez V, Grajales-Reyes JG, Robinson K, Pytel P, Báez-Pagán CA, Lasalde-Dominicci JA, Gomez CM.
Exp Neurol. 2015 Aug;270:88-94. doi: 10.1016/j.expneurol.2014.10.008. Epub 2014 Oct 23.